کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2533787 | 1559066 | 2010 | 8 صفحه PDF | دانلود رایگان |
![عکس صفحه اول مقاله: XLF-III-43, a novel coumarin–aspirin compound, prevents diabetic nephropathy in rats via inhibiting advanced glycation end products XLF-III-43, a novel coumarin–aspirin compound, prevents diabetic nephropathy in rats via inhibiting advanced glycation end products](/preview/png/2533787.png)
Advanced glycation end products (AGE) have been implicated in the pathogenesis of diabetic complications. The purpose of this study was to examine the novel coumarin–aspirin compound XLF-III-43 in the inhibition of AGE formation in diabetic nephropathy. In vitro analysis showed XLF-III-43 in a dose-dependent manner decreased glucose induced formation of glycation adducts on albumin and inhibited AGE–lysozyme crosslinking. The streptozotocin-induced diabetic rats were used to investigate the beneficial effects of XLF-III-43 treatment on diabetic nephropathy. Administration of XLF-III-43 significantly decreased (P < 0.05) blood urea nitrogen and urinary albumin excretion. Moreover, XLF-III-43 ameliorated kidney hypertrophy, mesangial expansion and glomerulosclerosis in diabetic rats relative to untreated model group. These data correlated with decreased both AGE and downstream markers of AGE stress (TGF-β1, CTGF, fibronectin and collagen IV fibrolysis) in kidneys of diabetic rats. These data support further development of XLF-III-43 for prevention of nephropathy via inhibition of AGE formation consequent to chronic hyperglycemia.
Journal: European Journal of Pharmacology - Volume 627, Issues 1–3, 10 February 2010, Pages 340–347